GlyCosmos Portal

Submissions

alectinib-resistant ALK mutants

Summary

Organism

Homo sapiens (human)

Reactome

R-HSA-9717316

PubChem

R-HSA-9717316

Description

Alectinib is a second generation tyrosine kinase inhibitor that is approved for use in ALK positive non-small cell lung cancers (NSCLCs). Alectinib is effective against a number of ALK mutants that arise after treatment with crizotinib, however resistance to alectinib has also been reported. This pathway describes ALK mutants that are resistant to inhibition with alectinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018; Hallberg and Palmer, 2016).

Click on a node on the pathway to see its details. Glycoproteins are marked with a glycoprotein icon in their name.

SPV: a JavaScript Signaling Pathway Visualizer, Bioinformatics, 2018

Displaying 1 entry
UniProt ID	Protein Name	Gene Symbol	Pathway Viewer
Q9UM73	ALK tyrosine kinase receptor	ALK	view

If you want to check the location of a particular molecule, you can do so by clicking on the "Switching Highlight" button on the page you have navigated to by clicking on "view".

About Release Notes Help Feedback

Click here to visit the beta site.